text:
Nine internationally acclaimed photojournalists have come together to put a lens on the effects of climate change. http://www.consequencesbynoor.com
Our photographs are stunning reminders of how climate change is effecting the earth. We would love to talk with you about featuring the project on your site
about consequences by noor
From the frontiers of climate change comes Consequences by NOOR. Featuring the work of nine, internationally acclaimed photographers, this exhibition documents the devastating effects of climate change around the globe. These stunning photographs show not what might happen in the future but what is happening today.
The subjects include: a massive pine beetle kill in British Columbia, genocide in Darfur, the rising sea level in the Maldives, Nenet reindeer herders in Siberia, Inuit hunters in Greenland, a looming crisis in Kolkata, India, coal mining in Poland, oil sand extraction in Canada and the deforestation of the Amazon Rainforest by Brazilian cattle ranchers.
Consequences by NOOR premiers at the United Nations Climate Change Conference in Copenhagen, December 7 through December 18, 2009.
Consequences by NOOR goes on tour in 2010 and is available for booking. Below is just one of the images from our project. I'd love to speak with someone to see if you'd be interested in featuring a few of the images on the wwfus website.


text:
A range of compact 2-way stereo speakers, with ABS enclosures and a sturdy metal grill. Suitable for free standing or wall mounting via adjustable fixing bracket. The trapezoidal design allows for the enclosures to be mounted neatly into corners, making them ideal for Hi-Fi and surround sound applications.
555-12090 - Stereo AM/FM Receiver with 50 Presets - 50W RMS x 2 Channels
Stereo AM/FM Receiver
Basic function stereo receiver is perfect in applications where 5.1 or 7.1 systems are not required. Designed for home environments, it is also ideal in small commercial environments for background music, where up to four speakers are to be ...
555-9975 - 40W X 2Ch Max Output Compact Stereo Amplifier
Compact Stereo Amplifier
Small amplifier is perfect when a line level source, such as a CD or DVD player, or portable MP3 player needs to be connected directly to a pair of speakers. It is perfect when an extra set of remote speakers, such as in-wall, in ceiling ...
82-20755 - Single-gang Mount Omni-directional Electret Microphone (no-preamp)
Surface Mount Omni-directional Electret Microphone (no-preamp)
The ML1-S is a low cost omni-
directional electret microphone
for use with I/P cameras accepting
microphone level input signals (PC compatible input). The attached
cord is 6' long and comes s...
24-14757 - 6' High Speed HDMI Cable with Ethernet
HDMI Cable with Ethernet
Take advantage of better looking movies, faster gaming and richer audio with the latest v1.4 high speed HDMI cables.Compatible with 3D and 4K display technologies, bi-directional A/V and data connectivity. It supports faster refresh rate...
24-14759 - 12' High Speed HDMI Cable with Ethernet
Good job MCM. I'm very pleased with all areas of dealing with MCM. Keep up the good work.

subset: commoncrawl


text:
eremy, Richard and James take a Lamborghini Gallardo Superleggera, a Porsche 911 GT3 RS and an Aston Martin V8 Vantage N24 to mainland Europe in search of the world's best driving road. Jeremy drives the Volkswagen Golf GTi W12 concept car. Dame Helen Mirren is the Star In A Reasonably Priced Car, and she explains the concept of public transport.Resumen IMDb.com
|Nombre del documento
|Top Gear - 10x01 - 07-Oct-2007 - ESP.srt


text:
|By CMR Rosa
|Part of the Destinies Rewritten continuity.
|Biographical information
|Physical description
|Hair color
|Eye color
|Personal information
|Weapon of choice
|Fighting style(s)
|Chronological and political information
Aang was born to two unnamed Airbenders in 12 BG who gave him to the monks at the Southern Air Temple. As an Air Nomad, Aang traveled extensively around the world. During his childhood, Aang was housed, raised, and educated at his home, the Southern Air Temple, under the custody of Monk Gyatso, who served as both a father figure and a counselor for Aang. As a child Aang was a member of the Air Scouts, where he learned essential skills such as how to tie reins to a bison's horns with the bison horn knot. When Aang turned six years old, he and several other young Air Nomad boys were taken to the Eastern Air Temple where they each chose a sky bison as their lifelong companion. Aang approached his soon-to-be pet sky bison Appa and offered him an apple, which Appa accepted, thus marking the start of their friendship. Aang had always been able to excel with any new bending moves he learned; at the age of six, he was a better Airbender than children twice his age, and by the age of ten, Aang had proven himself to be better than his own teacher.
While still a young boy, Aang had unconsciously revealed himself to be the Avatar when he chose the four Avatar relics out of thousands of various toys. In his childhood, Aang also visited the other Air Temples, as evidenced by his obvious familiarity with the Western Air Temple, as well as cities in the then-peaceful Earth Kingdom, such as Omashu, where he developed a lasting friendship with the good-natured but eccentric Bumi; he even bonded closely with children in the Fire Nation, like Kuzon, with whom Aang claimed to have gotten "in and out of so much trouble together". Due to the signs of a possible war approaching, Aang was told about his status as the Avatar at age twelve, four years earlier than the traditional age of sixteen, after exhibiting prodigious talent with his native element, Air. Aang felt burdened by his status and came to spend more time practicing Airbending with the monks rather than playing with his friends as he was used to. Monk Gyatso was the only one to show understanding to Aang's burden, having been good friends with Avatar Roku, Aang's past life, and tried to help ease Aang through the transition from childhood to adulthood by providing Aang with balance through fun during the upheaval in his life.
However, after learning that he'd be sent to the Eastern Air Temple in order to complete his Airbending training far away from Monk Gyatso, who other monks thought was too soft on him, Aang attempted to run away on his flying bison Appa. Shortly after running away, Aang and Appa were caught in a storm, crashing in the water and being swallowed by the waves. Aang saved himself and Appa while semi-conscious by entering the Avatar State, freezing the two in a sphere of ice by using a combination of Airbending and Waterbending. The Avatar State kept him alive, albeit not fully conscious, in the iceberg for about a hundred years.
See more
For the collective works of the author, go here.


text: Prodec Networks announces strategic partnership with Aruba Networks 07 Jan 2014 12:07 PM UK distributer adds Aruba Networks Wi-Fi products and solutions to its portfolio to further boost its unified communications offeringUK distributer Prodec Networks has formed a strategic partnership with wireless equipment manufacturer Aruba Networks. The partnership strengthens and complements Prodec Networks' unified communications offering, and was borne from Aruba's recognition of Prodec Networks' expertise and ability to offer something different to the market.Andrew Clark, Aruba Networks channel manager, said: "Aruba is very excited to be partnered with Prodec Networks. Prodec Networks' strategy for growth is in line with Aruba's vision and we believe this partnership will offer true value-add to the customer through solutions that will provide mobile agility, ease of management and true business benefits to the customer."As an Aruba Networks Silver Partner, Prodec Networks will offer the full suite of Aruba products and solutions at extremely competitive pricing. Further to this it will also offer a managed service of two key solutions, to suit businesses with mobility requirements beyond their in-house capabilities:The ClearPass Access Management System lets businesses create and enforce policies that extend across the network to devices and applications, giving them total control over mobility services and a simpler way to roll out Bring Your Own Device (BYOD).AirWave Network Management lets IT manage the application and device experience on several generations of multivendor networks.Kevin Hendy, Head of Solution Sales at Prodec Networks said: "In recognition of the ever increasing demand for BYOD in the workplace, Prodec Networks will be offering a unique managed solution for both ClearPass and AirWave for customers who want the responsibility of device and application management to be taken out of their hands."With a team of accredited and qualified sales and technical professionals offering a wealth of Aruba expertise between them, Prodec Networks said it is perfectly poised to assist businesses of all types and sizes with their mobility challenges.Prodec Networks was founded in 1998and partners with "best of breed" vendors to deliver solutions for businesses of all sizes. These solutions include data and wireless networks, mobile data connectivity, security, servers and storage.Prodec Networks said it also offers flexible solutions to budgeting challenges, including a buy-back facility whereby customers can offset old hardware against the cost of a new purchase, and a range of financing options.James Atkinson EditorLinkedIn |Google + |Email Leave a CommentPlease write code to prove you're humanMore on... Critical CommunicationsFinland and Norway sign cross-border TETRA communication dealCC Europe 2017: Hytera showcasing new base station and handheld radioMore on... AirwaveManaging the migration: the challenges and opportunities of ESNAvailability and resilience SLAs changed on new Emergency Services Network


text:
Lighting for Interior Design
|Malcolm Innes
|Portfolio Skills
|Malcolm Innes
|Portfolio Skills
Without light, interior architecture cannot be fully experienced. However, light can influence much more than our visual experience. Part One, Theory, looks at the physics and technology behind lighting. Part Two, Process and Practice, looks more specifically at the use of lighting in interior design and outlines the key design issues and principles. The book goes on to show the ways of representing lighting schemes using CAD and 3D models and how to implement and test these designs. Finally, the book explains how to deal with contractors, clients and other professionals. This book takes a detailed, practical look at lighting in interior design, giving students all the key information and skills they need to be able to tackle lighting successfully in their designs.
8 PART I THEORY 10 1. The physics of light 11 What is light? 12 The physical properties of light - what designers need to know 13 Reflection 14 Mirrors 15 Transparency 16 Filters and lenses 18 Refraction 19 Shadows 20 What is colour? 24 Quantifying light 25 Luminance 25 Candela 25 Lumen 25 Luminous flux 25 Lux 25 Illuminance 25 Light meters 26 2. Human factors 26 Sensing light 27 Adaption 28 Experiencing changes in light levels 29 Eyes and the sense of sight 30 Stereo vision 32 Motion detection 33 Low light sensitivity 34 Light and psychology 34 How do we see? 35 Preferences 36 3. Natural light 36 What do humans need? 38 Sources of natural light 40 Range of intensity 41 Direction of natural light 42 Colour and natural light 45 Daylight control 46 Case study: Architecture Gallery, Victoria & Albert Museum, London, UK 48 4. Electric light 49 Sources of electric light 49 Incandescent light sources 50 Discharge light sources 55 Electroluminescent light sources 57 Luminaires 58 Dispersive and directional luminaires 59 Concealed luminaires 59 Manufacturer's data 60 Generic luminaire types 62 Visualizing patterns of light 64 Visualizing spotlight data 65 Isolux diagrams 66 Lighting control systems 68 Mains voltage dimming 70 Electronic dimming 72 PART II PROCESS AND PRACTICE 74 5. Lighting principles 74 Visual hierarchy 76 Understanding qualities of natural light 77 Understanding layers of light 79 Change and variation 80 Creating drama through lighting 82 Changing and controlling light 86 Surfaces and texture 88 6. Lighting for people 88 How much light is enough? 90 Lighting for comfort and safety 91 Task lighting 92 Lighting for orientation 94 Step by step: Lighting a corridor 96 Case study: Wayfinding: Terminal 2F, Charles de Gaulle Airport, Paris, France 98 Avoiding glare 100 Case study: Low light gallery, St Mungo's Museum of Religious Life and Art, Glasgow, UK 102 7. Lighting for architecture 102 Ambient lighting 106 Accent lighting 110 Case study: One Gyle Square, Edinburgh, UK 114 Case study: Sheikh Zayed bin Sultan Al-Nahyan Mosque (The Grand Mosque), Abu Dhabi, UAE 120 Lighting vertical surfaces 121 Integrating light with architecture 122 Case study: Morimoto Restaurant, Philadelphia, USA 126 8. The design process 128 Researching the project 128 Analysis of needs 129 Outline proposal stage 129 Detail design stage 129 Construction stage 129 Final focus and programming 129 Client handover 130 Case study: St Machar's Cathedral, Aberdeen, UK 140 9. Recording and visualizing lighting 141 Drawing and sketching 142 Abstract representation 144 Diagrammatic representation 146 Photography 148 Computer renders as a design tool 150 Physical models 154 10. Project communication and completion 155 What is enough information? 156 Sections and elevation drawings 158 Case study: Musee de l'Orangerie, Paris, France 162 Lighting renders 164 Step by step: Using computer models 166 Recording circuiting and control intent 168 Use of sketch details 170 Lighting mock-ups and tests 172 Specification documents 172 Generic specification 172 Detailed specification 174 Realizing the project 175 Final focusing and programming


text:
Boulder Canyon Hickory Barbeque Potato Chips deliver a sweet, smoked flavor that takes you back to your favorite outdoor barbecue. These rugged, rich and tangy chips feature a robust combination of hickory flavor, garlic and onion in an all natural snack.
Boulder Canyon Chips are true favorites due to their intense flavor and crispy crunch. With seasonings that excite the senses, Boulder Canyon offers a variety of options for even the most finicky of taste buds. The bags are filled with deliciously thick cut and crunchy chips that burst with flavour. Unlike traditional potato chips, Boulder Canyon uses only the finest ingredients, making them a staple in any household.


text:
MILFORD, Conn. — A 4-year-old girl who fell onto the Metro-North tracks near the Milford Train Station was quickly rescued by her parents and other witnesses on Sunday afternoon, according to NBC Connecticut.
The Milford Fire Department also responded to help the girl, who was not seriously injured and did not require medical treatment, NBC said. The accident happened as she was getting off the train, NBC said.
Click here to read the story at NBC Connecticut.
To sign up for Daily Voice's email news alerts, click here and select your hometown.


text:
As Christ followers, we exist to bring glory to God by loving His people, spreading the Gospel, and making disciples. We were created to impact all nations for the glory of Christ. Matthew 28:19 commands us to "go and make disciples of all nations…"
At First Baptist Baytown, giving our lives is the missional aspect of our church. You can be involved in our mission by praying, volunteering, giving, serving, and going.
For those interested in going on a short-term trip, we ask that you follow the guidelines below:
Be a Christ-follower.
Must be able to attend team meetings and complete required training courses.
Must be a faithful member of a Bible believing fellowship. Although membership at First Baptist Baytown is not required, FBC members may be given preference in the selection process when spots are limited.
Have expressed agreement with First Baptist Church Baytown's Vision, Mission, Values, Strategy, and Statement of Beliefs.
Rehema Child Sponsorship
Valley Family Mission Trip in Mercedes, TX
Homeless Shelter
Christmas Store
A21-Walk for Freedom
"The Place" Apartment Ministry
Mission Arlington
Operation Christmas Child
Chainbreakers Ministry
Blast & Cast Men's Ministry
Mission Baytown (Coming Soon)
If you have any questions about missions or want to get involved contact Bekah Powell at or fill out the Interest Form.
Who can go on a mission trip?
All individuals and families are encouraged to inquire about any trip. The Missions Director will follow up on your inquiry. Most trips are entry level field training opportunities, but some trips do require special skills. All trip participants must give consent to a background check.
Do I have to be a member of FBC Baytown to participate in a mission trip?
No. Anyone is welcome but all applicants are subject to approval.
What is the process to go on a mission trip with Baytown's First?
- Complete the Mission Trip Interest Form.
- You will be contacted to follow up on your submitted interest form.
- Attend Mission Interest Meeting to learn more information about a particular trip.
I am interested in a trip but do not have a passport?
How can I get one?
No problem! You can find all the forms you need on the U.S. Department of State website.
We encourage everyone to own a passport. If the trip departs within 8 weeks of your need to renew or get a passport our Missions Director can guide you in the exact process to expedite your passport.


text: Start training in the water with the Aqua Sphere Water Exercise Starter Kit, which includes an aquatic exercise belt, dumbbells and a workout guide to get you going. The belt is made with EVA foam and features soft, rounded edges for comfort and buoyancy and adjusts for a secure fit. The dumbbells are designed with ergonomic handles to ensure easy use.


text:
Zuo Kong Ceiling Lamp
Kong ceiling lamp will bring a unique and industrial style to any home or office as the bell shaped is finished in distressed espresso surrounding a single light and is accented by an open weave metal cage finished in orange finish for added style and glamour. Bulbs not included. Bulbs sold separately, Max Watt 60 W, Size E26, Type A19. UL approved and listed.
Product Description
• Product Dimensions : 13.8" W X 13.8" D X 131" H
• Product Weight: 4 LBS
• Cord Length: 118"
• No. of Bulb Sockets: 1
• Bulb Type: A19
• Bulb Watts: 60W
• Socket Size: E26
• Color: Distressed Black
• Finish: Painted Metal
• Assembly Required: Yes
• Brand: Zuo
Additional Information
- VendorZuo
- Product TypeCeiling Lamps


text:
Delcath Systems (NASDAQ:DCTH)
Q4 2012 Earnings Call
March 13, 2013 4:30 pm ET
Douglas Sherk - Founder and Chief Executive Officer
Eamonn P. Hobbs - Chief Executive Officer, President and Director
Graham G. Miao - Chief Financial Officer and Executive Vice President
Matthew Dolan - Roth Capital Partners, LLC, Research Division
Jason N. Butler - JMP Securities LLC, Research Division
Gregory R. Wade - Wedbush Securities Inc., Research Division
Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2012 Delcath Systems Earnings Conference Call. My name is Derrick, and I'll be your operator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes.
I would now like to turn the conference over to Mr. Doug Sherk. You may proceed.
Douglas Sherk
Thank you, Derrick, and good afternoon, everyone. Thank you for joining us today for the conference call and webcast to provide an update on Delcath's fourth quarter and full year 2012 results and recent progress. A replay of the conference call will be made approximately -- excuse me, a replay of the conference call will be made available, and it will be made available approximately 2 hours after the conclusion of today's call. And it will be available for 7 days. The operator will provide replay details at the conclusion of today's call. A live webcast of this call is available at www.delcath.com, and the call will also be archived on the website.
Before we begin, I'd to remind you that some of the statements made during this conference call will contain forward-looking statements within the meaning of the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These statements are subject to certain risk and uncertainties, and actual results could differ materially from those projected in any forward-looking statements.
Factors that could cause actual results to differ are discussed from time to time in the company's filings with the SEC, including our annual report on Form 10-K and our reports on Form 10-Q and 8-K. These documents are available on the Investor Relations section of our website, and we encourage you to review the material. The company has no obligation to publicly update or revise these forward-looking statements to reflect the events or circumstances after the date they are made.
Participating on today's call are Eamonn Hobbs, President and Chief Executive Officer; and Graham Miao, Executive Vice President and Chief Financial Officer. Following their opening remarks, we'll open the call to questions from analysts and institutional investors. [Operator Instructions]
And now, I'd like to turn the call over to Mr. Hobbs.
Eamonn P. Hobbs
Thanks, Doug, and good afternoon, everyone. After making some opening remarks, including a brief review of our achievements during 2012, as well as our priorities and potential key milestones in 2013, I'll turn the call over to Graham Miao, our Chief Financial Officer, who will review the financial results for the fourth quarter. Then I'll take your questions.
We had numerous accomplishments during 2012. The most significant one was the acceptance for review of our NDA for the Melblez Kit system by the U.S. Food and Drug Administration. You'll note that we have changed the brand name of our system here in the United States, a decision that resulted from numerous discussions our team has had with the FDA since the NDA was accepted for review back in October. Melblez is our proposed brand name for melphalan. We continue to work closely with the FDA in its evaluation of our NDA, and we are quite focused on preparations for our presentation to the ODAC panel on May 2. Our engagement with the FDA has been constructive, and we are very hopeful that the agency will conclude its review on the PDUFA goal date of June 15.
Our team remains fully committed to bringing a new treatment option to U.S. patients with unresectable ocular melanoma liver metastasis. Assuming we are granted FDA approval by the PDUFA date, our current plan is to begin U.S. commercialization efforts in the fourth quarter of 2013. At this point, we would plan to market our product under the proposed trade name, Melblez Kit, which stands for Melblez melphalan for injection for use with the Delcath Hepatic Delivery System.
We continue to develop our U.S. launch plan for the Melblez Kit, with significant work being done in marketing, sales and reimbursement. As part of our planning, we have begun a comprehensive pricing analysis in the U.S. for the ultra-orphan disease state of unresectable metastatic ocular melanoma. There are currently no approved or effective treatment options for ocular melanoma metastatic to the liver, so there is a clear unmet clinical need among patients suffering from this disease. Our objectives with the pricing analysis are to optimize the value for treatment with the Melblez Kit, establish economic basis for reimbursement and ensure patient access to treatment.
Our initial marketing efforts in the United States would be focused on those hospitals that participated in our clinical trials and are part of our recently launched Expanded Access Program. These hospitals will provide a base of experienced procedure teams trained in the use of the Melblez Kit. Our focus will then expand to include other member hospitals of the National Comprehensive Cancer Network, which are Centers of Excellence for cancer care in the United States, that see a majority of the advanced metastatic ocular melanoma patients. To address this market, we plan to build a small direct sales force supported by medical science liaisons, which will provide clinical-based education to the health care professionals that make up the procedure team using the Melblez Kit.
With regard to our U.S. Expanded Access Program, its focus is to provide eligible patients with access to treatment with our second generation hemofiltration cartridge of the Melblez Kit while our NDA is under review by the FDA. Under the EAP, physicians that select U.S. cancer centers can use the Melblez Kit in expanded access and compassionate use cases, after they obtain Institutional Review Board or IRB approval. The first patient under EAP was treated in January at Sky Ridge Medical Center in Colorado and had a second treatment in February. The Moffitt Cancer Center in Tampa has also begun enrolling patients. We expect to enroll up to 6 prestigious U.S. medical centers that will offer patients access to the Delcath treatment option under the EAP program.
Because the Melblez Kit should be used by physicians with a certain level of knowledge and training, we are planning to train medical oncologists, surgical oncologists and interventional radiologists on the proper procedure using the Melblez Kit. As with many new products in oncology, the FDA has indicated that, if approved, the Melblez Kit will have a Risk Evaluation and Mitigation Strategies or REMS program, which will provide required training to all treatment team participants in the procedure utilizing the Melblez Kit. The REMS program will educate procedure team members on elements of safe use and training compliance. Our proposed REMS program will be part of the ODAC panel review on May 2.
As with many product launches in the first year, reimbursement can pose a significant headwind following FDA approval. As a result, assuming our NDA is approved by the FDA, we plan to take steps to position us for a successful launch of the Melblez Kit from a reimbursement perspective. Following FDA approval, we intend to interface with payers, both private and Medicare, to discuss compelling reimbursement and access to the Melblez Kit and the associated procedures. Assuming our NDA has been approved, we currently anticipate submitting an application for a Current Procedural Terminology or CPT Category I code in October of this year. With October 2013 submission, if the submission is approved, we anticipate the CPT would become effective in January 2015. In the interim, we anticipate that hospitals will use existing procedure-related codes to obtain reimbursement for Melblez Kit-related treatments.
One of our achievements in 2012 was the introduction of the CHEMOSAT Delivery System for melphalan in Europe. Following obtaining CE Mark for the Gen 2 system, we entered into training and marketing agreements with 16 leading European cancer centers. And today, 9 of these centers have been trained and activated to provide CHEMOSAT treatments. To date, these activated centers have treated patients with a variety of cancers in the liver, a majority of which have been ocular and cutaneous liver metastases but have also included hepatocellular carcinoma or HCC; cholangiocarcinoma; and liver metastases from breast cancer, gastric cancer, colorectal cancer, neuroendocrine tumors and mucosal melanoma. We are focused on 7 target European markets: Germany, United Kingdom, Italy, The Netherlands, France, Spain and Ireland. We market the CHEMOSAT system for melphalan in Germany, United Kingdom, Ireland and The Netherlands through a direct sales force; have entered into distribution agreements in Italy and Spain; and continue to seek a qualified distributor in France. We have also retained a contract field-based team of medical science liaisons to educate the medical oncology community in all 7 target markets.
A critical driver of utilization growth for CHEMOSAT in Europe, and ultimately revenue, will be the expansion of compelling reimbursement mechanisms for the procedure in each of the 7 markets we are targeting. Mechanisms for a partial reimbursement for the CHEMOSAT procedure have been established in Italy, and we are working with partner hospitals on supplemental reimbursement in specific regions.
In Italy, the CHEMOSAT procedure can be partially reimbursed under an existing diagnostic-related group code or DRG, allowing hospitals to submit for partial reimbursement of the CHEMOSAT device and related procedure. We are also assisting hospitals from certain regions in applying for supplemental new technology payments to increase the level of reimbursement. In the Lombardy region, the application decision has been complicated by political uncertainty, which we hope will be resolved following the recently concluded elections.
In addition, in conjunction with the European Institute of Oncology in Milan, we are evaluating the potential application for a new, dedicated DRG code specific to the CHEMOSAT procedure. In Germany, the federal reimbursement agency granted Value 4 status to our application under the NUB program, establishing a reimbursement pathway for CHEMOSAT procedures as a new technology treatment. While not mandating reimbursement, Value 4 status allows participating cancer centers to negotiate reimbursement for the CHEMOSAT procedure with all insurers serving the region. This Value 4 status has resulted in some of our participating cancer centers in Germany initiating negotiation with all payors that cover their region. While reimbursement is sought under the Value 4 status, we intend to work with partner hospitals to resubmit an application for Value 1 status after our Phase III trials are published, which we hope will occur later this year.
In the United Kingdom, leading cancer centers are seeking to gain primary care trust or PCT interim funding, which we hope will be granted in the second quarter of 2013. PCT funding would allow CHEMOSAT procedures to be performed at those key centers that apply, with referrals being made nationwide. We are working closely with 5 of the key melanoma centers in the United Kingdom to achieve this interim funding. Due to current health care reforms in the United Kingdom, in April 2013, interim funding for oncological procedures will begin to move away from local PCTs to a centralized body, which may offer an opportunity to gain nationwide interim funding more quickly. Time frame for completing this change is currently unknown.
We are also engaged with the Healthcare Resources Groups or HRG that decide on new HRG codes with a view to gaining a dedicated and permanent reimbursement code. At the same time, the National Institute for Clinical Excellence or NICE may decide to conduct a review of the CHEMOSAT procedure at any time, the outcome of which would determine our long-term reimbursement status. However, we do not anticipate an assessment from NICE until a significant number of CHEMOSAT procedures are conducted regularly in the United Kingdom.
Permanent compelling reimbursement in remaining EU markets will take some time to secure. And in the interim period, we are seeking payment through various avenues, including new technology programs. For example, in France, in order to obtain a permanent DRG code, the level of required data, both in terms of clinical trials and health care economics, is extremely high compared to other countries in the EU. We believe we will need the published Phase III trial manuscript supported by investigator-initiated trial data before submitting our application. We anticipate submitting our application in late 2013. And in the meantime, we are targeting the private market in France. Phase III publication is also a gating item for reimbursement in Ireland.
Development of compelling permanent reimbursement is a key driver of utilization, and we are working closely with experts in our partner hospitals on various interim mechanisms. We have begun the applications project to secure compelling permanent reimbursement. Though these mechanisms have come online slower than we anticipated, which has impacted revenue ramp, physician interest in our therapy is strong. And we remain optimistic about the long-term prospects for CHEMOSAT in Europe.
Now I'd like to review our clinical development program. We are very excited about what we consider to be a robust clinical development program, the primary goal of which is to expand our U.S. label indication beyond the initial indication we are seeking into much larger opportunities and also support clinical adoption and commercialization efforts in markets outside the United States. We believe execution of this program will ultimately drive long-term shareholder value.
Over the longer term, we also intend to evaluate the technology platform for use with a variety of chemotherapeutic agents for the treatment of other liver cancers, as well as other organs and body regions. Our top priority is to pursue potential label expansion opportunities for our CHEMOSAT Melblez Kit system with melphalan in the treatment of other more prevalent cancers in the liver. We are moving forward with plans for clinical trials in hepatocellular carcinoma, also known as HCC or primary liver cancer; metastatic colorectal cancer; and neuroendocrine tumors with liver-dominant disease. We are in active discussions with the FDA on these proposed multicenter trials. And subject to their agreement, we intend to begin enrolling patients for at least one of these new clinical trials in 2013.
In Europe, we plan to initiate a patient registry, which we will prospectively collect data from EU clinical experience. This registry will serve as a standardized safety and efficacy database and as a means for clinicians to collaborate and share CHEMOSAT clinical experience and outcomes from up to 15 centers in all 7 key EU markets.
We are also seeking to build clinical experience by sponsoring investigator-initiated trials or IITs with leading EU opinion leaders that have approached us to support new clinical research. We believe these IITs will help grow clinical experience with CHEMOSAT at key centers and will support our effort to obtain compelling reimbursement for CHEMOSAT. In Taiwan, we are collaborating with our strategic partner, Chi-Fu Trading Company Limited, on a pivotal trial with melphalan for HCC with the intent of obtaining regulatory approval from the Taiwan FDA.
Looking longer term, we believe that our proprietary drug device platform may have broader applicability, including using other drugs to treat the liver as well as for the treatment of cancers in other organs and regions of the body. As such, we currently have active development programs for the isolation and treatment of the lung and brain cancers. We are also pursuing pharmaceutical partners to co-develop and fund clinical trials related to additional indications for our technology.
Turning to other anticipated key milestones in 2013. We have been working with the principal investigators of our Phase III melanoma and Phase II multi-histology clinical trials and believe that submission of the clinical data to a peer review journal for publication could occur in the next several weeks. Additionally, publications characterizing the European clinical experience using the CHEMOSAT system and the clinical benefit of treating liver metastases have either been recently submitted or are in progress. In addition, we continue to work at leveraging the CE Mark for CHEMOSAT in order to expedite approval in other select countries, as we have already done successfully in Australia and New Zealand. During 2012, we submitted applications for regulatory approvals for the CHEMOSAT system for melphalan in Hong Kong, Singapore, Argentina and Brazil, and expect to receive approvals in most of these markets in 2013.
We are pursuing strategic partners for development of CHEMOSAT in the People's Republic of China. As you know, in October, we obtained the right to affix the CE Mark to the CHEMOSAT Delivery System for doxorubicin. China represents a potentially large market for the Delcath CHEMOSAT Delivery System for doxorubicin with its primary liver cancer or HCC incidence accounting for an overwhelmingly large majority of the world's primary liver cancer patients.
With that, I'd like to turn the call over to Graham Miao for a review of our financial results, and then we'll take a few questions. Graham?
Graham G. Miao
Thank you, Eamonn. Good afternoon, everyone. Let me begin by providing an update on the company's financial condition.
We raised approximately $21 million from our at-the-market or ATM facility between January 1, 2013 and February 28, 2013. And that program has been successfully completed. As a result, our cash balance as of February 28, 2013, was approximately $38 million. Because the ATM equity program has worked well for us since its inception in December 2011, and as part of our efforts to strengthen our balance sheet, we have entered into an agreement with Cowen and Company to renew our ability to use the ATM equity financing strategy. We have a shelf registration designated for the ATM program, which we filed for review with the SEC this afternoon after the market close. Under the new agreement, Delcath may sell up to approximately $50 million in shares of the company's common stock from time to time, once the new shelf registration statement becomes effective. We believe this complements our existing committed equity financing facility and strengthens our ability and flexibility to access capital.
As a reminder, the committed equity financing facility or CEFF was established last December, and we used that month -- we used that facility that month to validate its utility. As of February 28 this year, the CEFF program has up to $32.8 million remaining with Terrapin Opportunity Fund. We believe that with our current cash balance and access to capital under the CEFF and ATM programs, we have the flexibility to execute our operating plan for the next 12 months and beyond.
Turning to use of cash. Our cash utilization in the fourth quarter 2012 was $9.7 million, representing a 33% reduction compared to $14.6 million in the third quarter last year. This was consistent with the company's previously announced expectations for average monthly cash spend between $3 million and $4 million for the fourth quarter. The decrease in cash utilization was primarily driven by a reduction in consulting services following submission of the NDA, as well as overall effective cost management. We remain committed to maintaining our reduced cash utilization of between $9 million to $12 million a quarter for 2013.
Turning to the income statement. During the fourth quarter, we recorded revenue of $0.2 million. Operating loss was $11.8 million, which included approximately $0.9 million in non-cash stock-based compensation expense, as compared with an operating loss of $16 million, including $0.9 million in non-cash stock-based compensation expense in the same prior-year period.
Selling, general and administrative, SG&A, expenses were $6.4 million for the fourth quarter of 2012 compared to $6.1 million for the same period in 2011. The higher SG&A expense was primarily due to the increased EU commercialization expenses. Research and development, R&D, expense were $9.6 million for the fourth quarter 2012 compared to $9.8 million for the same period in 2011. The lower R&D expenses reflect lower consulting expenses, following the submission of the NDA on August 15, 2012.
For the year ended December 31, 2012, we recorded revenue of $0.3 million and additional $30,000 of deferred revenue related to the orders from distribution partners. The company's operating loss was $53.9 million, which included approximately $3.8 million in non-cash stock-based compensation expense. The increase in expense is primarily related to EU commercialization efforts. Operating loss for the year ended December 31, 2011, was $46.5 million, which included approximately 6 -- excuse me, $4.3 million in non-cash stock-based compensation expense. SG&A expenses were $28 million for the year ended December 31, 2012, compared to $21.3 million for the year ended December 31, 2011. R&D expenses were $26.2 million for the year ended December 31, 2012, compared to $25.2 million during the year ended December 31, 2011.
As Eamonn mentioned, we expect the revenue ramp to be slow in the near term until further progress is made on reimbursement front in Europe. We are continuing to work hard at establishing procedure reimbursement mechanisms in our target countries, which we believe in combination with increased clinical experience in Europe, will help support future revenue growth. Finally, we will be presenting at the Roth conference on Monday -- next Monday, March 18, at 3:00 p.m. Eastern Time. In addition, we'll be conducting a non-deal roadshow in Chicago next Thursday, March 21.
And now, I'll turn the call back to Eamonn.
Eamonn P. Hobbs
Thank you, Graham. To conclude, in 2012, we achieved a material reduction in our cash burn and had our NDA accepted for review by the FDA with a PDUFA date of June 15, 2013. We begin 2013 with a robust clinical development program in place and are making progress on obtaining reimbursement in Europe and have adequate cash and access to capital to execute our plans. Though challenges remain, there's much to be excited about. And we look forward to updating you on our next quarterly call.
With that, operator, we're ready to take questions.
Question-and-Answer Session
[Operator Instructions] Our first question is from the line of Matt Dolan, Roth Capital Partners.
Matthew Dolan - Roth Capital Partners, LLC, Research Division
I wanted to get a little more on your reimbursement strategy in the U.S. Now that you have narrowed the label you're pursuing, how does that play in to what you're expecting from a reimbursement perspective? And if you could tie in what you anticipate upon launching Q4 under the 99 codes, and then what might come through the Category I. And how we should think about pricing as a result?
Eamonn P. Hobbs
Well, our plan for the United States is, as we mentioned, to utilize existing codes, including the 99 codes until the new procedure codes, Category I CPT codes, are approved and issued in 2015. So we'll have a little over a year prior to that to deal with existing codes. Our -- with relevance to the change in the indication, narrowing to ocular melanoma, since there is no established treatment and this is a completely unmet need for ocular melanoma patients with liver-dominant disease, we will be relying heavily on the unmet need pathway and our Phase III clinical trial data to support reimbursement efforts by hospitals who are conducting the procedure. Because this is a ultra-orphan market, we would anticipate and we're currently working on a pricing strategy that would be reflective of an ultra-orphan marketplace. The therapy is a combination of the cost of our drug system, the Melblez Kit; and also the procedure reimbursement, which would be a DRG, ultimately. So there is a little more complexity on the reimbursement side than if this was just a drug. So to summarize, it's currently a work in progress. On the pricing side, we anticipate that the pricing will be more reflective of an ultra-orphan market size than our current financial estimates in our investor presentations. And as soon as that's completed, we'll update those, which I would anticipate to be potentially by our next investor update.
Matthew Dolan - Roth Capital Partners, LLC, Research Division
Okay, appreciate that. And maybe just to clarify one point, so the reimbursement that you'd obtain would be at a premium but include only the ocular melanoma patients. Is that correct?
Eamonn P. Hobbs
Well, if your question relates to the potential for reimbursement under 99 codes for off-label use...
Matthew Dolan - Roth Capital Partners, LLC, Research Division
Eamonn P. Hobbs
Apologies, I didn't understand that originally. The procedure for gaining reimbursement is going to be based on clinical data as it always is. So the question in my mind would be, would there be sufficient clinical data for a hospital to obtain off-label reimbursement based on our Phase II data, which was multi-histology in NET, HCC, cholangiocarcinoma and NET? So the answer to that question is going to be in the eye of the beholder, in the eye of the payor, as to whether that rises to the level of substantial or significant clinical data to support reimbursement. So I'm afraid we're not going to know that until a hospital actually applies for it, whether or not they'll be able to get reimbursement. And I'm not sure there's any way to gain any insight in that, that would be very robust at this time.
Matthew Dolan - Roth Capital Partners, LLC, Research Division
Okay. And the second topic I wanted to touch on was the European ramp. You mentioned it'll be fairly slow until reimbursement gets ironed out. But you gave us a procedure target last year. Is there anything you could give us from either centers or procedures or timing of clarity on reimbursement that might help us model out that side of the business?
Eamonn P. Hobbs
Well, thanks, Matt. All we can say about reimbursement is the majority of our activities at this point are focused on gaining reimbursement. We've created a very solid beachhead in our 7 target markets, with clinical centers performing procedures. And now, all of our efforts really are focusing on pursuing -- helping them pursue reimbursement. And where we are in that process, we went through in the presentation, it is a clearly work in progress, and it varies country to country. The publication of our clinical data, both our Phase III and our Phase II, factors into that. The Value 4 status we -- was an achievement for us under the NUB program in Germany, which now allows the many hospitals that signed up for the program to pursue reimbursement. And we have yet to have a hospital complete that process. We have multiple centers that have applied for reimbursement under that program, and we're awaiting the outcome. So the Italy partial reimbursement has been established. We are looking to bolster that. So unfortunately, from a modeling perspective, we are at the mercy of factors outside of our control as to if and when these reimbursement mechanisms come online. And the good news is we believe they are coming online, albeit a bit slower than we had initially hoped. And we will keep you apprised as they happen.
Your next question will be from the line of Jason Butler, JPM.
Jason N. Butler - JMP Securities LLC, Research Division
Eamonn, just wondering if you could give us any color on your current interactions with FDA? And maybe give us an overview of what you are preparing to -- or expect the FDA and the Advisory Committee to focus on during the panel? I know you talked about REMS, but maybe you could talk about what, in terms of efficacy or safety, you might expect the focus to be.
Eamonn P. Hobbs
Jason, our -- definitely, the tone of our FDA interactions has been very constructive. We're having very routine interactions with the agency, a lot of back and forth. A tremendous amount of the interactions are related to the REMS program, and we anticipate ODAC is going to be very heavy on the REMS side. We have been told that FDA anticipates that there'll be at least 1, if not 2, interventional radiologists on the ODAC panel, which is obviously very unique but very applicable from the perspective that this is both a procedural and a medical oncology new technology. So we would anticipate that there'll be some procedural aspects of the Melblez Kit procedure and the -- and also the usual ODAC interactions with regards to the safety. And a tremendous amount, since this is so procedurally oriented, of the anticipated agenda will be associated with REMS. Now having said all that, the ODAC is a work in progress. We -- although we're in heavy preparation mode for ODAC, we won't submit a briefing package for ODAC until April 2, a month before the May 2 ODAC. And we won't receive the questions until, literally, hours before the meeting so -- or even the tone of the subject matter until a few hours. But those are our best guesses at this point. And we are looking forward to being very, very well prepared for the May 2 ODAC.
Jason N. Butler - JMP Securities LLC, Research Division
Okay, great. And then my apologies if I missed this earlier. But can you talk about what the use of the Expanded Access Program has been so far and what you expect it to be?
Eamonn P. Hobbs
Well, the EAP program kicked off in very late January at Sky Ridge in Denver, our first site. And a ocular melanoma patient was treated and then -- successfully, and then was treated with a second round of therapy, which we believe is a very good sign, in February. The Moffitt Cancer Center in Tampa, we anticipate will be the -- is enrolling patients and will be the second site to initiate procedures very, very shortly. We anticipate that up to 6 centers will be involved in the EAP. But with all the variables associated with IRB approvals and patient scheduling, it's very hard to predict patient throughput for the EAP. Our anticipation, longer term, is that by PDUFA date, we would anticipate we would have all, if not the majority, of the EAP sites up and doing procedures. There's certainly significant interest for them to do so.
Your next question is from the line of Greg Wade from Wedbush.
Gregory R. Wade - Wedbush Securities Inc., Research Division
A couple quick questions. With respect to getting some Gen 2 safety data in for the AdCom, what's the procedure for that? And then the follow-up question is with respect to pricing. I mean, it seems like you've got a choice with respect to pricing here in the U.S. Go with probably a very high price, which might price you out of the off-label utilization or something lower in which off-label utilization may be more commonplace ahead of getting the label expanded. Can you just help us understand how you're grappling with this decision and what maybe market research you've done to help guide you in making it?
Eamonn P. Hobbs
Sure. Well, Gen 2 data into the AdCom has always been something we've been very interested in providing. And with the European experience and the current EAP program under way, we are collecting data on Gen 2 use that we plan to make available to the agency. The actual mechanics of how that data will be presented to the ODAC are pretty straightforward in that they'll be part of our briefing package and presentation. And certainly, we'll be ready with slides to answer any questions that are presented at ODAC. So a pretty standard AdCom situation is what I'd anticipate any Gen 2 issues being addressed with. With regard to pricing, it is a very good point. Clearly, our clinical development program broadcasts our belief and ambitions to broaden the label in the United States for our technology to far larger markets that we believe will be, hopefully, very well served by the technology as demonstrated by clinical trials. So all that being said, after our hopeful approval for our initial indication, the on-label indication is going to be ocular melanoma, which is a relatively small patient population to be served but a very, very significant unmet need in that patient population. So where we are is we -- our pricing strategy is a work in progress. We're working with outside experts to put together a cogent pricing strategy. And my -- although the strategy isn't completed yet, my crystal ball, if you will, would suggest that we will end up with more ultra-orphan pricing than mainstream, large market pricing since our -- for a number of reasons: one, our initial indication is ultra-orphan; and two, it is extremely questionable whether pricing would have that – an effect, if any, on any potential decisions to use the product or not, considering the life-threatening aspect of the underlying disease. So I would hope that the pricing differential wouldn't factor into the clinical benefit equation as to whether or not it's appropriate for a patient that may not have the on-label indication. But -- and that's clearly not our call.
[Operator Instructions]
Douglas Sherk
We have a question from the webcast participants. Can you please provide an update on the Canadian approval process, please?
Eamonn P. Hobbs
Certainly. To update investors about where we stand with Canada, we had applied in Canada as a device based on our CE Mark approval for our CHEMOSAT for the delivery of melphalan system approval and had made tremendous progress with the Canadian device regulatory authorities with regard to the potential approval and felt that we were getting very close to that approval based on interactions with them. At the very tail end of that approval process, the drug side of the Canadian health care regulatory authorities made a decision that, like the U.S., the system should be regulated as a combination product, requiring a new label for melphalan in Canada. With that in mind, we withdrew our device application and are now considering what our options are with regard to applying for a combination product approval in Canada, which most certainly would not take place prior to a U.S. FDA approval. So at this point in time, the -- any decisions to be made regarding Canada are tabled until we get past our PDUFA date.
Douglas Sherk
Another question from the webcast participants is, with the cash balance at the end of February, about $38 million, can you explain the reasoning behind the timing for renewing the ATM now?
Eamonn P. Hobbs
Certainly. The rationale for renewing the ATM right now is really associated with the ability to use the ATM in an opportunistic manner, based on windows of opportunity that may or may not present themselves. So hypothetically, if the stock price went on a run to a very high value, which it has done in the past, that -- if we had an ATM in place, we would be able to avail ourselves of that opportunity and avail the investors with a financing that would be minimally dilutive compared to a financing or a more classic financing at a lower stock price. So the real advantages of the ATM program center around the ability to access capital at the lowest dilutive manner that is available to us via various financing mechanisms. Also the discounts and expenses associated with the ATM program are extremely competitive, if not far more advantageous, than other financing mechanisms. So the combination of being opportunistic and speed to be able to access a hot market, if you will, plus the very low overhead costs and expenses associated with the ATM program, make it very attractive for us to have an ATM program at our disposal as part of a multi-pronged strategy to provide access to capital for the company. As Graham mentioned in his presentation, we also have an existing committed equity financing facility that provides us access to capital in a different way but, in some ways, provides us access to windows of opportunity, maybe not as -- quite as -- at quite the speed that the ATM program does. And then, of course, we have other mechanisms that we've used in the past, such as secondaries and the like. So the reason to put an ATM program in place today -- to initiate the start of an ATM program today is because our old program, we feel, was very successful, provided access to capital at a very low cost and that program has expired. So we'd like to have a new one at our disposal that would be available for use at opportune moments in the future.
We have an audio question from the line of Marshall Barrow [ph], Incumbent Fund [ph].
Unknown Analyst
On that, how long -- on the ATM program, how long does that stay effective, once it's approved by the SEC or reviewed by them?
Eamonn P. Hobbs
3 years.
Unknown Analyst
Okay. And the other question I have is these patients that are being treated, you said there's one and you expect another handful or so. On the EAP program, can that -- is that information used in connection with the Advisory Committee or the FDA meetings?
Eamonn P. Hobbs
Yes, it certainly is. All the information associated with the EAP program is readily available to the FDA, since it's part of a clinical trial that is ongoing in the U.S. And we definitely assume that, that data will be utilized by the agency in the Advisory Committee.
Unknown Analyst
Did you anticipate that there'll be any news releases concerning how -- the progress for those patients?
Eamonn P. Hobbs
No. That would be very, very unusual, if not outside the rules, to present any interim results associated with a clinical trial. But FDA would be -- would have very, very realtime understanding of how well those patients would be doing.
Douglas Sherk
We have time for one more question on the -- from the webcast participants. That is, can you just review the U.S. market size for metastatic ocular melanoma?
Eamonn P. Hobbs
Sure. Well, the number of patients in the United States, we anticipate, is -- that have unresectable ocular melanoma that's liver dominant is approximately 1,600 -- or approximately 1,700 patients out of a total that is approximately twice that. So approximately 50% of patients with ocular melanoma develop liver-dominant unresectable disease and are what we would consider to be ideal candidates. Now with regard to the market size, there are 2 other factors that come into play: the number of procedures that each of those patients would receive, and if we look to the Phase III, the average patient received approximately 3 procedures per treatment regimen. And so that would appear to be a very reasonable estimate for market size. Lastly, we'd apply the cost or the average selling price of the system in the United States. And the system, of course, in the United States, the Melblez Kit, if approved, would be sold as a combination product, including both the drug and device. And in our current investor presentations, we use $25,000 per procedure that would go to Delcath. The -- as we mentioned earlier, we are currently studying and evaluating ultra-orphan pricing that we would anticipate would be significantly higher than $25,000 per procedure. But having said that, our current investor presentation utilizes the conservative $25,000 per procedure, and that would equate to an on-label market size for ocular melanoma of $105 million for the U.S.
Douglas Sherk
There are no further questions from the webcast participants.
Eamonn P. Hobbs
Okay. Thank you. Thank you, everyone, for joining us today. And we look forward to keeping you updated on our progress as we move forward. All the best.
Ladies and gentlemen, that concludes today's conference. We thank you for your participation. You may now disconnect. Have a great day.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: email@example.com. Thank you!


text:
Connecting Families to Senior Living
Talk to a local advisor for FREE
Talk to a local Advisor about this community
Contact this community at:
(866) 333-2174
29250 West 10 Mile Road
Farmington Hills,
Caretypes Provided: Independent Living
Pricing is available for the following rooms:
*Prices quoted are monthly rental charges and are provided by the communities themselves. Actual prices may differ due to one-time fees, timing and care services required. Speak with your Senior Living Advisor to learn more.
Our apologies. Pricing is currently unavailable for this particular community.
Serving Residents with Excellent Care, Endless Hospitality and Open Hearts Come discover Sanctuary! At Sanctuary at Marian Oakland, seniors enjoy freedom, independence and privacy when they choose it — security and support when they need it. Our affordable, cozy Independent Living apartments provide the ultimate in convenience and individualized services within a warm and friendly environment. Residents can enjoy life-enriching community activities, going on group outings or just relaxing without maintenance worries. Sanctuary at Marian Oakland is owned and operated by Trinity Senior Living Communities, a leading advocate of holistic, individual-first health care.
Schedule an appointment with an Advisor
out of 18 reviews
Marian Oakland
"When my mom fell for the fourth time in her home, it was time
to move quickly to get her into a safe/welcoming environment. I
didn't know where to start or what to do next. I was so stressed!
When you came to my rescue, it was such a huge relief to
know I wasn't in this alone. Your organization is a true
Melody L., Found Assisted Living in Plymouth, MI
"I truly appreciate the help and encouragement you provided to
my husband's parents and our family during these past few months.
The information you shared with us was a definite factor in
helping us make this transition and I am sincerely thankful for
Nancy K., Found Assisted Living in Detroit, MI
We are thrilled with the facilities & care at Sanctuary at Marian Oakland. Our father is living in a beautifully kept, safe environment & he loves it. There are many activities & trips, new friends... more...
Call Now (866) 333-2174
Get the latest tips, news, and advice on aging and caregiving.
A Place for Mom is the largest assisted living referral service. We are paid by our participating communities, therefore our service is offered at no charge to families.
Copyright ©2017 A Place for Mom, Inc. All rights reserved.


text:
If you have an existing online account, sign in below.
Shop with confidence.We value your privacy and security
Item Number:
Your Savings:
Shipping & Handling:
(5 reviews)
Please enter your personalized text to appear on your item.
You are adding more than 1 item with the same personalization to the cart.
The following personalized text will appear on all these items:
The following personalized text will appear on your item:
Make Changes
This item is currently sold out. Please check again at a later date.
For more information, please contact 1-888-2020-888.
Ratings & Reviews
(average rating based on 5 reviews)
Ratings Distribution
5 Stars
4 Stars
3 Stars
2 Stars
1 Stars
of respondents would recommend this to a friend.
Reviewed by 5 customers
Sort by
Displaying reviews 1-5
Back to top
Love it x2
By TSC Aholic
from Mississauga
I ordered the watermelon and just ordered the platinum...should I say anymore :)
Bottom Line Yes, I would recommend this to a friend
( 2 of 2 customers found this review helpful)
I Have Been Searching For These!
By tsc regular shopper
from Calgary
I love Madreperla from the island of Majorca Spain where I once was a long time ago on a fab cruise trip where I was first introduced to Madreperla.The island is as magical as their pearls I remember...Having just tried Judith R pearl drop earrings and finding them to be way too heavy for me although GORGEOUS , I was hesitant about ordering these based upon reading Nancy's review where she mentions the earring has "a little bit of weight."All I can say is compared to the JR pearl drops I tried these Madreperla drops are for me light as a feather - don't feel any weight AT ALL - just the dangle lets me know they're there!!!I chose the white and the pearls are large, natural looking and luminous!I just came back to order the bright watermelon and the platinum as these are just too good to pass up!On top of everything else - they have my closure of choice - the leverback, easy to put on and easy to take off, let's the ear breathe where piercing is, and unlike the millions of earrings on TSC with fish hooks and fiddly rubber stoppers - No Loss with these babies!I think highly of these, perhaps because I just experienced a much much heavier pearl drop earring where I had to remove them after only a short period of time because of the weight of them.
By LARRAINE
from DUNDAS
Bought these to match a necklace from the same line. Really happy with my purchase. A good size which is noticeable but not to big. Great quality in this line.
( 1 of 2 customers found this review helpful)
Good size
By KJ
from Montreal
The pearls are a good size so they can be seen which is something I wanted like the reviewer says below. I ordered all four colours but just keeping the white and watermelon/red ones as they suited me best.
( 6 of 6 customers found this review helpful)
A Great Earring!
By Nancy
I bought 3 colours and all of them are well made. It was exactly what I was looking for - a pearl earring that you can see, and that really highlights the face. The pearls are luminous; the earring has a little bit of weight but it is not heavy. I would have given 5 stars but the leverback portion is standard, albeit sturdy enough.


text:
The fully air-conditioned hotel, which was built in 2007, offers a total of 86 rooms, including 26 suites, all of which are elegant, modern and exclusive in design. Facilities include: lobby with 24-hour reception, hotel safe, currency exchange, cloakroom, lift access, caf�, bar, 2 restaurants, conference facilities, WLAN/ Internet access, 24-hour room service and a laundry service, as well as a bicycle rental service. The hotel also offers complimentary parking.
The hotel is situated by a magnificent 18-hole golf course. The centre of Layos, which offers various restaurants, is only a 5-minute walk away and there is a lake and forest only 15 minutes away on foot. Toledo can be reached in only 5 minutes on public transport where guests will find various bars and discos. Public transport is situated only 20 m from the hotel. The hotel is located less than 9 km from Toledo and is well connected to the capital by the motorway (A-42), by train (AVE 9 km) and by bus. Madrid-Barajas Airport is 90 km away.
The rooms are comfortable and all come equipped with minibar, complimentary Internet access, en suite bathroom, hairdryer, direct dial telephone, satellite/ cable TV, double or king-size beds, individually adjustable air conditioning and heating, a safe and a terrace. It is possible to book rooms for guests with disabilities.
The hotel offers outdoor sports facilities such as swimming pool with sun loungers, parasols and a sun terrace, as well as a paddle court. The Medispa offers a bathing area with a dynamic swimming pool, alternating showers, snow fountain, sauna, Jacuzzi, Turkish bath, relaxation area, treatment suites, massages and a gym, as well as the most advanced treatments in aesthetic medicine. Canoeing, rowing, mini-golf and golf can all be enjoyed at an extra charge. Hunting and horse riding are also options.
The hotel offers a breakfast buffet as well as dinner � la carte in either of the two restaurants in the hotel. There are also salons available for banquets with a capacity for up to 400 persons.
American Express, Diners Club, JCB, Maestro, MasterCard, Red 6000 and VISA are all accepted at the hotel.
Roads towards Toledo: A-42 Railcar Madrid - Toledo. N-400 to Cuenca, Albacete and the Spanish Levant (Route Oca�a). N-403 Avila, Salamanca and Valladolid. A-V Talavera of the Queen, Herv�s and Caceres. AP-41 Railcar of Toll Madrid - Toledo. Road to Layos: Exit 68B off the A-42. Direction (address) Arg�s. Ctra. Off Toledo to Piedrabuena, 12 km. Layos.
The reception desk is open 24 hours. Parking is complimentary.
Room Facilities:
Direct dial telephone
Satellite cable TV
Internet access
Double bed
King size bed
Individual airconditioned
Individual heating
Wheelchair accessible
Disabled bathroom


text:
by antonia
(Brooklyn, new york)
Lord I came before saying thanks for giving favorable answers to my prayers. Lord I'm not feeling good and my pressure is a little high as well as swelling in my left foot, Lord you are the miracle worker and I know your precious blood will cleanse me of whatever,s ailment trying to overtake me. Lord again I say thanks for healing and favorable answers and may your will be done in my life. I love you lord and I give you the highest praise ALLELUIA.
Join in and write your own page! It's easy to do. How? Simply click here to return to Prayers for Strength.
Click for Inspiration
50 Inspirational Bible Verse Pictures
See What Happens After A Single Act Of Kindness
By The End of This Video, Your Faith Will Be Stronger Than Ever
See What Happens When Someone Pays For A Random Stranger's Groceries
Popular Prayers
Must Reads:
5 Powerful Prayers for Prosperity
Does God Answer Prayers?
8 Prayers You Need to Know by Heart
The Trick to Powerful Prayer


text:
Find a copy in the library
Finding libraries that hold this item...
|Large type books
Psychological fiction
|Material Type:
|Document Type:
|All Authors / Contributors:
Mitch Albom
|0375432329 9780375432323
|OCLC Number:
|322 pages (large print) : portrait ; 20 cm
|Mitch Albom.
|More information:
"Eddie is a grizzled war veteran who feels trapped in a meaningless life of fixing rides at a seaside amusement park. Then, on his 83rd birthday, Eddie dies in a tragic accident, trying to save a little girl from a falling cart. With his final breath, he feels two small hands in his -- then nothing. He awakens in the afterlife, where he learns that heaven is not a lush Garden of Eden, but a place where your earthly life is explained to you by five people who were in it. These people may have been loved ones or distant strangers. Yet each of them changed your path forever. One by one, Eddie's five people illuminate the unseen connections of his earthly life."--Jacket.
User-contributed reviews
Similar Items
Related Subjects:(17)
- Accident victims -- Fiction.
- Amusement parks -- Fiction.
- Amusement rides -- Fiction.
- Future life -- Fiction.
- Older men -- Fiction.
- Heaven -- Fiction.
- Death -- Fiction.
- Large type books.
- Psychological fiction.
- Accident victims.
- Amusement parks.
- Amusement rides.
- Death.
- Future life.
- Heaven.
- Older men.
- Aged men -- Fiction.


text:
Unique to O2 customers, the Blackberry Curve 8310 can now be purchased in a stylish red colour. With all the same capabilities as the original, the Curve 8310 remains the smallest and lightest of all the BlackBerry smartphones to offer a full QWERTY keyboard.
Despite its small dimensions (107x60x15.5mm), the BlackBerry Curve 8310 packs in a fully functional GPS system, and O2 customers will be able to enjoy other features such as a speakerphone, voice dialling, Bluetooth and an Instant Messaging service. As with all BlackBerry smartphones, users can organise and sync their red Curve 8310 with their PC to store calendar data, address books and much more.
It's not the first time O2 has teamed up with RIM to produce an exclusive BlackBerry handset. The BlackBerry Pearl 8110 is already available to O2 customers in blue and pink.
For further information on price and availability speak to your local O2 store or visit www.my-blackberryfromo2.com.


text:
Get 10% off all titles + free UK p&p. Offer applied at checkout
Simon Jenkins
An indispensable companion to England's most beautiful places from Simon Jenkins, author of A Short History of England, England's Thousand Best Churches and England's Thousand Best Houses.
A book to treasure from the supreme champion of Britain's heritage
With superb photographs by Paul Barker, it is a timely reminder, if one were needed, of the beauty of this country of ours and the need to savour what we so often take for granted
A beautiful book ... the mix of photographs and prose, covering everything from Dartmoor to the Cheviots, is still stirring.
Book of the year
Picture book of the Week
Customer Service
Online Shopping
Join Us
© 2015 Profile Books Ltd.
3 Holford Yard, Bevin Way
London WC1X 9HD
Email: firstname.lastname@example.com
Phone: + 44 20 7841 6300
Registered in England & Wales under No. 3120147
VAT Number 674 9638 76
Web development by Firsty Group


text:
Reviews - Hartnoll Hotel4
Bolham,, Tiverton, EX16 7RA
Customer Reviews
Our reviews are from genuine LateRooms.com customers. We verify that the customer has stayed before leaving a review.
Very Good
83% would recommend it to a friend
Customer service
Food quality
Room quality
Great to stay with a dog!!
A lovely hotel
I really liked the art work and ambience in the hotel
First class food and service.
Room somewhat cramped, disliked the integrated bathroom. Towels would not be changed if hung on towel rails...there were none so left on side of bath, no doubt to the confusion of the staff who changed them anyway. Toilet extremely small with toilet seat set at an angle?!
Read More Less
Fantastic service.
We have stayed here a few times and it never disappoints.
The food is amazing and the service is second to none. Everyone is friendly and welcoming and I would thoroughly reccomend it to anyone.
Read More Less
- < previous
- 1
- page 1 of 1
- > next


text:
Working in finance and Tech in Canary Wharf.
Absolute kitchen wizz.
Good movies are a must. How anyone lives without them is beyond me.
Love sports, avid Chelsea fan but watch most when they're on the square shaped box.
Trying to find the chill for my Netflix
listen to most music as long as i can dance to it (surpisingly i dont always have to be drunk for this to happen).
And I won the high school award for "most likely to die during freshers week".
Trying to jet off to as many great places as possible, though not half as many as most travellers on here.
Would be particularly greatful if someone could help me build my list of places I (hopefully we) have been.
What a gent I can be.
Music -anything apart from heavy metal.
I couldn't possibly forget food, I'll eat pretty much anything apart from olives and oysters.
Restaurants, well gbk and Nandos if I'm honest,but I wouldn't say no to a pizza express.
Generally, who I'm holidaying with next, what would inspire me so much I'd want to do it for life and is anerica really going to elect trump, really America.


text:
Pez for Pets Dog Treat Dispenser
Possibly one of the coolest ways to dispense your pets treats, training them to use it is another story!
Limited edition Hello Kitty pez dispensers! They come in a cool lunchbox case also!Tags: hello kitty, pink, candy, limited edition, pez, Pez DispenserAdded 9 Years Ago from Urban Outfitters


text:
- published: 28 Jul 2017
- views: 736
Actors: Georg Friedrich (actor), Detlev Buck (actor), Lukasz Simlat (actor), Alice Stengl (miscellaneous crew), Martina List (costume designer), Michael Glawogger (director), Michael Glawogger (writer), Nicolas Steil (producer), Erich Lackner (producer), Tadeusz Szymków (actor), Witold Wielinski (actor), Michael Ostrowski (actor), Michael Ostrowski (writer), Victor Varnado (actor), Elzbieta Heleniak (miscellaneous crew),
Plot: A comedy of absurd situations and misunderstandings. Hans and Max would like to corner the local hot dog market, whereas Harry would prefer to be pampered by his muscular auto mechanics. But a bag with mysterious contents interrupts everyone's plans, and the group of improbable thieves and gangsters suddenly find themselves in Poland's Drogomysl.Genres: Comedy,
Actors: Sunny Deol (actor), Rana Jung Bahadur (actor), Sudesh Berry (actor), Sukhwinder Singh (composer), Atanas Apostolov (miscellaneous crew), Sardar Sohi (actor), Sumeep Kang (actor), Monalisa (actress), Anil Yadav (actor), Sambhavna Sheth (actress), Sana (actress), Ammtoje Mann (writer), Ammtoje Mann (actor), Ammtoje Mann (director), Anand Mishra (actor),
Plot: India in the new millennium is faced with corruption, unemployment, crime, and all-round insecurity. Many want to travel abroad to better their lives. Rashid Khan is an individual who assists them, albeit illegally, by taking huge amounts, and then transporting them to their choice of destinations, which in this case is Britain. A group of about 200 people use their lives' savings and pay Rashid, chief amongst them are dishonored Indian Army Officer Aman Kumar Sahadev; Banwari and his nephew, Prem, from Uttar Pradesh; Rajnam Venkateshwaram from Tamil Nadu; Santokh Singh from Punjab; Prof. Proveer Chatterjee from Kolkata, while others hail from Gujarat, Mumbai, Haryana, Rajasthan, Jammu, and also include people from Bangla Desh and Pakistan. This trip turns out to be nightmare as their presence is intercepted and they go into hiding and face hunger amongst other problems. They must now leave to board a ship, which encounters a storm, capsizes, killing hundreds, and leaving only a handful. They land on shore, and are met with Aman's ex-girlfriend, Niharika, who is now married to a man she does not love. Her father is a scientist who is in possession of plutonium. He gets killed, and a dying Niharika, who has been fatally shot, gives the plutonium to Aman. They travel onto Afghanistan where they are met by their guide, Palvisha, who also takes charge of the plutonium so that she can hand it over to the Northern Alliance who want to rule Afghanistan. Palvisha soon finds out that the Northern Alliance is up to no good, takes possession of the plutonium and travels to Kazakhstan, where they meet their new guide, Sameer, who decides to assist them for a huge fee. They survive many perils, and share a common bond, while someone or the other in their group always ends up getting killed by thugs, authorities, and illness. Things change dramatically when they enter Pakistan - and it is here they will all be arrested and held in prison cells - and it is here they will find the true identity of Sameer - who is not who he claims to be.Genres: Action,
Actors: Michaël Abiteboul (actor), Ángel Hernández Zoido (editor), Jacky Nercessian (actor), Lola Dueñas (actress), Carmen Machi (actress), Alain Rimoux (actor), Avelina Prat (miscellaneous crew), Jérôme Vidal (producer), Pedro Pastor (producer), Damián París (producer), Javier Rebollo (director), Javier Rebollo (writer), Jean Fornerod (actor), Franck Fuchs (miscellaneous crew), Piluca Baquero (producer),Genres: Romance,
Actors: Paul Haggis (producer), Hilary Swank (actress), Margo Martindale (actress), Clint Eastwood (producer), Mark Thomason (actor), Riki Lindhome (actress), Michael Peña (actor), Jay Baruchel (actor), Jude Ciccolella (actor), Anthony Mackie (actor), Ming Lo (actor), Clint Eastwood (actor), Morgan Freeman (actor), Tom Rosenberg (producer), Gary Lucchesi (producer),
Plot: Frankie Dunn has trained and managed some incredible fighters during a lifetime spent in the ring. The most important lesson he teaches his boxers is the one that rules life: above all, always protect yourself. In the wake of a painful estrangement from his daughter, Frankie has been unwilling to let himself get close to anyone for a very long time. His only friend, Scrap, an ex-boxer who looks after Frankie's gym, knows that beneath his gruff exterior is a man who has been seeking, for the past 25 years, the forgiveness that somehow continues to elude him. Then Maggie Fitzgerald walks into his gym...Keywords: adrenaline, age-difference, ambulance, amputation, asking-for-help, assisted-suicide, based-on-short-story, birthday, bottled-water, boxer
Actors: Renny Harlin (producer), Steve Dorff (composer), Jenifer Lewis (actress), Christopher Walken (actor), Sissy Spacek (actress), Alicia Silverstone (actress), Nikita Khrushchev (actor), Rex Linn (actor), Fidel Castro (actor), Dave Foley (actor), John F. Kennedy (actor), Brendan Fraser (actor), Nathan Fillion (actor), Anne Fletcher (miscellaneous crew), Unjoo Lee Byars (miscellaneous crew),
Plot: Adam Weber is the child of an eccentric inventor and his wife. Following a bomb scare in the 1960s that locked the Webers in their bomb shelter for 35 years, Adam Weber must venture out into Los Angeles and obtain food and supplies for his family. He meets Eve, who reluctantly agrees to help him out.Keywords: 1960s, adult-bookstore, affection, airplane-accident, attraction, automobile, baseball, beach, belt-massager, bomb-shelter
Actors: Rosa Maria Sardà (actress), Antonio Carmona (actor), Penélope Cruz (actress), Fernando Colomo (writer), Joaquín Oristrell (writer), María Barranco (actress), Fernando Colomo (director), Miguel Ángel Santamaría (editor), Josep Maria Pou (actor), Lolita Flores (actress), James Fleet (actor), José Miguel Carmona (composer), Juan Carmona (composer), Edmon Roch (producer), Beatriz de la Gándara (producer),
Plot: Luis, a Spanish student,goes to London to get a course in Economics. He lives at a house the neighbour of her aunt, but when she broke up with her husband, Luis goes to live with her.Keywords: aunt-nephew-relationship
Actors: Georg Danzer (composer), Hans-Gerd Kilbinger (actor), Karl-Heinz Bender (actor), Uwe Karsten Koch (actor), Hans Fuchs (actor), Francesco Santucci (composer), Tim van Beveren (producer), Tim van Beveren (director), Tim van Beveren (writer), Ernesto Lutter (actor), Andrea Matzker (actress), Helmut Rubarth (miscellaneous crew), Tania Wyoroba (actress), Rosemarie Schulz (actress), Helmut Rubarth (actor),Genres: Drama,
Actors: Eric Sykes (actor), Sam Kydd (actor), Joan Sims (actress), Ned Sherrin (producer), Warren Mitchell (actor), John Bird (actor), Roy Kinnear (actor), John Le Mesurier (actor), Arnold Diamond (actor), Dandy Nichols (actress), Roy Hudd (actor), Nosher Powell (actor), Beryl Vertue (producer), Derek Griffiths (actor), Johnny Speight (actor),Genres: Comedy,
Actors: Penny Daniels (miscellaneous crew), Malcolm McDowell (actor), Stanley Myers (composer), Bryan Forbes (director), Norman Bird (actor), Bryan Forbes (writer), Marianne Stone (actress), James Payne (actor), John Savident (actor), Bernard Lee (actor), Geoffrey Bayldon (actor), Gerald Sim (actor), Nanette Newman (actress), Barry Jackson (actor), Michael Nightingale (actor),
Plot: Bruce Pritchard is paralysed in a soccer game and is confined to a wheelchair in a convalescence home. But this doesn't slow his lust for life. Then he meets Jill and has to think about the effects of disability.Keywords: disability, flirt, independent-film, paraplegic, sex-between-handicapped
Actors: John Warwick (actor), Kenneth Tsang (actor), Anthony Buckley (editor), Harold Hopkins (actor), Alistair Duncan (actor), Ken Goodlet (actor), Noel Ferrier (actor), Michael Aitkens (actor), Redmond Phillips (actor), Bob Young (composer), Gerard Maguire (actor), Slim DeGrey (actor), Max Meldrum (actor), Doreen Warburton (actress), Kerry Dwyer (actress),Genres: Drama,


text:
Welcome to Olympia Fields Advice is a click away
What Would You Like To Know?
Olympia Fields
The land that sits under the village today was once farmland used by immigrant families during the 1830s. The Illinois Central Railroad began servicing the village in the 1850s, which doubled the population and economic growth during that era.
Olympia Fields has received the Tree City USA award for several years of having shown a commitment to caring for and up keeping the village's public trees.
The village is two miles east of I-57.
- Metra Electric
- Olympia Fields Station
- Randolph St Station
- School District 170 (Kennedy School)
- Flossmoor School District 161 (Western Avenue Elementary School)
- Flossmoor School District 161 (Parker Junior High School)
- Homewood-Flossmoor School District 233 (Homewood-Flossmoor High School). Homewood-Flossmoor High School is a three-time recipient of the U.S. Department of Education's Blue Ribbon Award for excellence. HF also owns WHFH 88.5, the highest powered high school radio station with 1,500 watts.
- Matteson School District 162
- Rich Township High School District 227 (Rich Central High School)
- Bloom Township High School District 206 (Bloom High School)
Notable People
- Barbara McKinzie, Alpha Kappa Alpha's twenty-seventh International President, who served from 2006 to 2010
- Dee Dee Davis, actress and comedian best known for her role as Bryana "Baby Girl" Thomkins on The Bernie Mac Show
- Jim Osborne, former defensive tackle for the Chicago Bears
- Kendall Gill, retired professional basketball player
- Toi Hutchinson, a Democratic member of the Illinois Senate representing the 40th District
- Rudolph Isley, singer-songwriter and a founding member of The Isley Brothers[13]
- J. Ivy, Grammy Award-winning poet
- R. Kelly, R&B singer-songwriter and producer
- Nnedi Okorafor, a Nigerian-American writer of fantasy, science fiction, and speculative fiction; winner of the World Fantasy Award for Best Novel and the Wole Soyinka Prize for African Literature
Property Listings
Property listings for Olympia Fields, Illinois.
Market Analysis
Market analysis data for Olympia Fields, Illinois.
Real Estate Market
Median sale price last 12 mo.
Avg. property tax
Sale price lowest 12 mo.
Sale price highest 12 mo.
Area and Demographic Statistics
This part graphically explains area and demographics stats for Olympia Fields, Illinois.
|Population Density
|Median Age
|Average value of the dwelling in which household lives
|Avg. years a household has lived in dwelling.
|18 years
This part contains all educational institutions in Olympia Fields, Illinois.
School Name Phone Type Grades Rating Homewood Christian Academy Not Available Private PK-8 Arcadia Elementary School 708-747-3535 Public KG-4
School Name Phone Type Grades Rating Homewood Christian Academy Not Available Private PK-8 Arcadia Elementary School 708-747-3535 Public KG-4
School Name Phone Type Grades Rating Homewood Christian Academy Not Available Private PK-8
School Name Phone Type Grades Rating Rich Central Campus High School 708-679-5600 Public 9-12
The Best in Olympia Fields
Browse through the top rated businesses in the most popular categories Olympia Fields, Illinois has to offer.


text: Ritter swings budget ax at prisons, human services By on August 22, 2009 By Jason Kosena THE COLORADO STATESMAN Gov. Bill Ritter's bleak Tuesday budget update had one bright spot: It's not as bad as it could have been. On Tuesday, Gov. Bill Ritter, surrounded by Democratic lawmakers, talked about further budget cuts the state must make in coming weeks to balance the budget. Due to the recession, […]This content is only available to subscribers. Login or Subscribe Share this:EmailTwitterFacebook Current News, Title Item


text:
Eh...I don't know what to think of this.
Disclaimer is no longer necessary.
She strolled into the dank and dim room, hands stuffed deeply into pockets that didn't quite mask the fact that they'd been curled into fists. The strobe light affect of each game clawed at her eyes as Abby tried to look calm and angry at the same time. She pulled down her cap, glaring dangerously as two mossy-toothed boys leered at her, their eyes red from staring at a screen for who knew how long. Their creeping eyes made her quicken her pace just the slightest. Abby coolly ignored the catcalls, nearly hidden behind the blips of gameplay, as she slid to the back, where a lone figure stood hunched over the machine that was slowly stealing his soul.
"Abby curses that pinball machine." She whispered into his ear, hoping to catch him off guard. Hoagie turned and grinned at her, leaning against the metal front of the game smugly.
"Jealous much?"
Her plump lips turned downward in a scowl. "Yes." She met his gaze with thinly veiled worry. "Ya been in here every day after school, playin' this stupid game!" Abby slammed a hand onto the ancient glass in emphasis and frustration. The screen shuddered and she removed her hand quickly, shooting it a distrustful look. It winked merrily back at her. "Ya got a life, Hoags. Don't throw it away on this."
His usually sweet demeanor turned sour as he returned to the game. Abby stared at his blue clothed back in surprise before furrowing her brows in anger. Using the power she'd built up in her seventeen years, Abby pushed him away from the pinball machine and planted herself on top of it, crossing her arms defiantly. Her eyes challenged him to ignore her. His sky blues were soft and guilty.
"Go away, Abby." Hoagie murmured, looking away. "I don't see why it concerns you." She gaped at him.
"Why does it concern me? Hoagie, ya my best friend! I don't wanna see ya throw away everything on something stupid!"
"Who says I've thrown anything away?"
Abby took a deep breath and met his eyes evenly. "How much money have ya spent on this game this week?" He sighed, resigned.
"Twenty bucks." Her eyes widened. Considering that the machine took only quarters, a feat such as this increased her worry tenfold.
Keeping the disappointment from her voice as best she could, Abby continued her guilt trip. "And how're ya grades?" Hoagie's eyes hit the floor in shame and when he spoke, the tears clouded his voice.
"Not good." He looked up suddenly, his eyes glassy, and ran his fingers through unruly auburn hair. "Abs, what am I going to do? This thing is eating me." Abby smiled. Progress was a great thing.
Hopping off the whirring machine, she slipped into her stern face. "Ya gonna leave with me and never come back to this place. We gonna go to ya house and we gonna study. No backtalk. March." She pointed to the door, playfully serious. He snapped her a salute and grabbed his ratty blue bag from the floor. Abby waited until his back was turned and, quickly enough to make anyone watching think it had been an accident, wrapped her foot in the cord that brought life to the pinball machine and ripped it from the socket. The prongs bent at different angles, the black rope of electric life support wouldn't be able to steal her best friend's sanity any longer.
Don't pull cords! Anyway...came to me as I pursued the High Score of Addam's Family Pinball. It's addicting, lemme tell you.
I'm sort of proud of this one, though it is full of OOCness. Review?
Love always,


text: Meta Battle Subway PokeBase - Pokemon Q&A Login Register All Activity Questions Unanswered Tags Users Ask a Question Rules Chat User Pokemon Master 9999 Wall Recent activity All questions All answers Wall for Pokemon Master 9999 Please log in or register to post on this wall. . . . Jan 25, 2015 by kuroyoru Sup Feb 10, 2014 by Natsu Useful Meta Posts Vote for Sun/Moon moveset questions How to change your username How to add a user avatar Why was my post hidden? The points system Question etiquette Flags vs Downvotes Anime FAQ


text:
With First Tutors: Music you can locate a Laindon cornet teacher. Cornet tuition are an excellent method to start a stimulating new hobby, pick up a new skill and attain confidence with cornet. Use our service to search for Laindon cornet teachers and choose which suits your requirements so you can begin your cornet tuition in Laindon today!
First Tutors: Music is the best place to discover Laindon cornet tutors in the UK, helping you discover Laindon cornet lessons in your area and Laindon tutors to assist with any instrument, for example, piano, violin or guitar. We can help you find Laindon cornet lessons or a one-to-one Laindon cornet tutor to prepare for cornet grades and develop your cornet skills! Our search will order Laindon cornet teachers near you according to their lesson charges and proximity to you.
If you are a cornet tutor wishing to offer cornet lessons in Laindon or throughout the UK, please register with First Tutors: Music or find out more about us here. Becoming a Laindon cornet teacher is a fantastic way to improve your own skills through giving cornet lessons while assisting someone else, all in your local Laindon area!


text: Compensation Plan Compensation due to Municipalities ÉEQ is required to compensate 100% of the efficient and effective eligible net costs of municipal curbside recycling services for materials in the "containers and packaging" and "printed matter" classes. In Quebec, approximately 560 municipalities and municipal organizations receive an annual compensation for the curbside recycling services they provide. RECYC-QUÉBEC is the government agency responsible for turning over the compensation to municipalities in accordance with the Regulation respecting compensation for municipal services provided to recover and reclaim residual materials. Over the past 10 years, contributing companies paid municipalities almost $1 billion in compensation. It is therefore imperative for ÉEQ to get involved in optimization at every step of the value chain.


text:
CantFaketheFunk Edit
68. Neil Marshall
Being related to Jake Marshall gives you points. Also he apparently had an awesome fight scene with Joe Darke... only one that we didn't see. And he won the King of Prosecutors award, so he must have been pretty cool. Also, his death kinda sucked.
Cloud and Squall Edit
33rd: Neil Marshall
Appearances: 1-5
Favorite Quote: None
Neil Marshall seemed like a good guy, especially for a prosecutor. The way he saved Ema's life was nothing short of Heroic. I was a bit worried in case 1-5 about him writing Ema's name down. It didn't seem quite like something that he would have done. I was glad to learn that it wasn't the case. Thought I had suspected it for quite a while. For a character that you never really meet, Neil was really cool. I wouldn't mind a Mia Fey: Ace Attorney game with him as a prosecutor in it. It seems like he'd be like Post-Crisis Miles Edgeworth. I like how he had a cowboy motif just like his brother. I felt bad for him. Not even killed by Joe Darke. His brother was right- he wouldn't just lose in a fight like that. I had thought about that. I think that's when I started thinking about Damon as a suspect.
DNEA Edit
36. Neil Marshall
Um... he's Jake's brother and managed to get a prosecutor award? I think that's enough to make him better than bloody Grossberg...
Naye745 Edit
59. Neil Marshall
i wish we'd gotten to know him better :(
but for a character with almost no development whatsoever he made 59th so bravo
Paratroopa1 Edit
51. Neil Marshall
Hmmm, I think Neil's the highest non-appearing character on this list, and for good reason. He's just totally awesome. He's related to Jake, which is awesome of course, and then unlike most victims in the series he doesn't die without a fight and gets killed being a heroic badass. I'll bet he was a pretty kickass prosecutor and would've been higher on this list if he was alive. Oh well.
SSBM_Guy Edit
64. Neil Marshall
Case(s): SL-9
Yet another victim. Neil is cool. He's the less cooler of the two brothers, but...he's still awesome. He was awesome enough to get the King of Prosecutors award, too. That takes some pretty good skill. Sucks that he had to die, just so Gant could get to blackmail Lana and take control of the Prosecutor's Office. Yeah...Neil got screwed. What I want to know is why Neil is dressed as a cowboy, too. Jake said that he dressed as a cowboy, because of a special he saw a few weeks ago and inspired him to be a cowboy. But...if SL-9 happened 2 years before Case 1-5...then why is Neil dressed as a cowboy? <_< I always found that sorta weird.
transience Edit
68. Neil Marshall
- well he seemed cool
- last names go a long way
WiggumFan267 Edit
59. Neil Marshall
Another guy I'm conflicted on. It's really hard to rank the victims who obviously would have been highly rated if you had interaction with them... And again, involved with the cool case. I guess it's good that he didn't kill Darke on some level, but not on another, cuz then he wouldn't have been Ganted if he killed Darke and wasn't knocked out...... Also um... hey man, your vest, it hates me. Cool character, I guess, maybe? ;_;
Leonhart4 Edit
86. Neil Marshall
The Good: He's Jake's older brother, so that's a good start. He also wears an awesome hat. Plus, the guy won the King of Prosecutors Award when Manfred von Karma was still prosecuting. That's pretty hardcore.
The Best: He won a fight in the dark against Joe Darke trying to save Ema's life. He seems like a really good guy, one of those honest prosecutors.
The Bad: It's too bad that he went out the way he did, getting used as a piece of blackmail by Gant over Lana. Also, he's one of those guys you'd like to meet but you never do, so that hurts his rating.
The Worst: The guy got KO'd by a 14-year-old girl and the Blue Badger Jar. That's not cool.